Risk factor
Very poor trading liquidity
Profitability factor
Favourable price performance
About
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer’s disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.